Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05974839
  4. Details
NCT05974839 Clinical Trial

Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)

Primary Progressive Multiple Sclerosis Clinical Trial

— ORATORIO-Cort  

Official title:
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With Primary-progressive Multiple Sclerosis Participating in the ORATORIO: a Post-hoc Analysis of a Double-blind, Randomized, Phase 3, Placebo-controlled Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT05974839
Other study ID # 00007536
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 1, 2023
Est. completion date September 30, 2025

Study information
Verified date April 2024
Source State University of New York at Buffalo
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.

Description:

To study the effect of ocrelizumab on cortical lesion accumulation in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomized, phase 3, placebo-controlled study.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 732
Est. completion date September 30, 2025
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patient participating in the ORATORIO study - MRI scans available at baseline - Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 2D/3D T1-WI at baseline Exclusion Criteria: - None

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Ocrelizumab
Non-interventional

Locations
Country Name City State
United States Buffalo Neuroimaging Analysis Center Buffalo New York

Sponsors (2)
Lead Sponsor Collaborator
State University of New York at Buffalo Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Cortical lesion number accumulation Cortical lesion accumulation as measured using MRI between subjects on placebo and subjects who took ocrelizumab. 5 years
Secondary Cortical lesion number accumulation and disability. Cortical lesion number accumulation as measured by MRI for subjects who developed disability over the course of the placebo-controlled phase of the study. 5 years
See also
  Status Clinical Trial Phase
Completed NCT02549703 - Mitochondrial Dysfunction and Disease Progression
Recruiting NCT02273635 - Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Phase 1/Phase 2
Withdrawn NCT05029609 - Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS Phase 1
Terminated NCT03283826 - Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis Phase 1/Phase 2
Active, not recruiting NCT05974852 - Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
Recruiting NCT04977622 - Gray Matter Demyelination in Primary Progressive MS at 7T
Recruiting NCT05893225 - Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration Phase 2
Completed NCT03094364 - Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis N/A
Completed NCT02253264 - A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Phase 1
Recruiting NCT03691077 - Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 Phase 3
Completed NCT00950248 - Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) Phase 1/Phase 2
Active, not recruiting NCT05232825 - A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis Phase 3
Recruiting NCT05229861 - The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS N/A
Completed NCT01077466 - Natalizumab Treatment of Progressive Multiple Sclerosis Phase 2
Completed NCT01854359 - Idebenone for Primary Progressive Multiple Sclerosis Phase 1/Phase 2
Completed NCT03493841 - Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis Phase 1
Active, not recruiting NCT03562975 - Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Completed NCT00731692 - FTY720 in Patients With Primary Progressive Multiple Sclerosis Phase 3
Recruiting NCT04943289 - Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis Phase 1
Completed NCT01779934 - OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis Phase 3